
Mitralign
Founded Year
2004Stage
Series F | AliveTotal Raised
$153.68MLast Raised
$9.77M | 6 yrs agoAbout Mitralign
Mitralign develops a catheter-based technology for percutaneous treatment of functional mitral regurgitation. It emulates surgical annuloplasty delivering a series of surgical implants directly into the mitral annulus by means of a catheter. The company was founded in 2004 and is based in Tewksbury, Massachusetts.
Loading...
Loading...
Mitralign Patents
Mitralign has filed 46 patents.
The 3 most popular patent topics include:
- actuators
- cardiac anatomy
- cardiac surgery

Application Date | Grant Date | Title | Related Topics | Status |
---|---|---|---|---|
4/18/2018 | 6/29/2021 | Actuators, Linear motion, Linkages (mechanical), Medical equipment, Dosage forms | Grant |
Application Date | 4/18/2018 |
---|---|
Grant Date | 6/29/2021 |
Title | |
Related Topics | Actuators, Linear motion, Linkages (mechanical), Medical equipment, Dosage forms |
Status | Grant |
Latest Mitralign News
Nov 26, 2022
Atlanta-based medical company Nyra medical raises USD 20 million in Series A funding By Nyra Medical, Inc., a medical device business developing a revolutionary transcatheter mitral valve replacement technique, announced the completion of a USD 20 million Series A fundraising round. Vensana Capital and an extensive global medical device company led the round, with Epidarex Capital, Broadview Ventures and the Georgia Research Alliance Venture Fund also participating. The funds raised will support Nyra’s technology through early feasibility clinical trials. Nyra is developing a transcatheter device (CARLEN) that changes the native mitral valve leaflets using a unique implant to rectify inadequacies that might otherwise result in mitral regurgitation while retaining physiological valve shape. “We now know that correcting mitral regurgitation in heart failure patients can reduce mortality and hospitalization rates, with earlier intervention yielding the best results,” says Murali Padala, Ph.D., inventor of CARLEN, Director of Emory University’s Carlyle Fraser Cardiothoracic Research Laboratories, and founder of Nyra Medical. Eric L. Sarin, MD, co-founder of the firm: “A transcatheter therapy that may enhance effectiveness and safety while remaining simple is the ‘holy grail’ of structural heart disease treatment. The Nyra team recognized this fact and designed an elegant device that meets numerous current requirements in treating valvular heart disease.” Amrinder Singh, Principal at Vensana Capital, stated: “The transcatheter mitral repair market is still in its early stages, with plenty of possibilities for expansion. Nyra’s technology offers an elegant treatment option and is a logical next step in the progression of catheter-based advances for treating mitral regurgitation. Our team and clinical advisors are very excited about CARLEN’s potential as a treatment for mitral valve disease. With this fresh round of funding, Nyra has appointed Lisa Wipperman Heine as an independent director to its board of directors. Lisa is a seasoned medical technology professional with over 25 years of experience in operational, management, and board positions. She was most recently the CEO of preCARDIA. Before that, she was the COO of Mitralign and held several leadership positions at Covidien, including Global Vice President of Medical Affairs for Vascular Therapies. More about the company: With the motto ” Simplifying transcatheter repair of heart valves…one valve at a time,” Nyra Medical is a medical device company that develops the CARLEN technology, the transcatheter technology for the treatment of mitral regurgitation. CARLEN help preserves the natural valve form while restoring function, eliminates the potential of stenosis, and preserves future transcatheter and surgical therapy options. We try our best to fact-check and bring the best, well-researched, and non-plagiarized content to you. Please let us know -if there are any discrepancies in any of our published stories, -how we can improve, -what stories you would like us to cover and what information you are looking for, in the comments section below or through our contact form! We look forward to your feedback, and thank you for stopping by!
Mitralign Frequently Asked Questions (FAQ)
When was Mitralign founded?
Mitralign was founded in 2004.
Where is Mitralign's headquarters?
Mitralign's headquarters is located at 3 Highwood Drive, Tewksbury.
What is Mitralign's latest funding round?
Mitralign's latest funding round is Series F.
How much did Mitralign raise?
Mitralign raised a total of $153.68M.
Who are the investors of Mitralign?
Investors of Mitralign include Oxford Bioscience Partners, Forbion, Triathlon Medical Venture Partners, Accelerated Technologies Partners, Square 1 Bank and 15 more.
Who are Mitralign's competitors?
Competitors of Mitralign include NeoChord, Cardiac Dimensions, Spectrum Medical, Ancora Heart, Benvenue Medical and 7 more.
Loading...
Compare Mitralign to Competitors

NeoChord is a medical technology company engaged in the advancement of beating heart mitral valve repair in patients suffering from mitral valve regurgitation. The company's flagship product, the NeoChord Artificial Chordae Delivery System, is a beating heart procedure, echo-guided treatment for patients with mitral valve regurgitation, and is proven to resolve and restore normal mitral valve function. It was formerly known as mValve. The company was founded in 2007 and is based in St. Louis Park, Minnesota.

Cardiac Dimensions develops minimally invasive treatment modalities to address heart failure and related cardiovascular conditions. Its initial technology platform, the CARILLON Mitral Contour System has been designed to address functional mitral regurgitation, utilizing a novel percutaneous approach. The company was founded in 2000 and is based in Kirkland, Washington.

Avertix develops an implantable cardiac monitoring and alerting system to warn cardiac patients of potentially life-threatening heart conditions. It offers heart monitors that track changes in the heart's electrical signal from a pacemaker lead. It identifies the symptoms of acute thrombotic occlusions by alerting the patient to seek medical attention. The firm was formerly known as Angel Medical Systems and changed its name to Avertix in April 2023. The company was founded in 2001 and is based in Eatontown, New Jersey.
Cardiac Power is a non-blood-contacting left ventricular assist device for the treatment of congestive heart failure
Bio Control Medical offers implantable devices for the treatment of incontinence and congestive heart failure.
CardioKinetix develops a percutaneous treatment for patients with left ventricular dilation after an anterior myocardial infarction (MI). The implantable device, called the PARACHUTE is a partitioning membrane deployed within the compromised ventricle. The PARACHUTE partitions the damaged muscle, isolating the non-functional muscle segment from the functional segment, and decreases the overall volume. Options for patients whose ventricle has enlarged are limited, with most on medical therapy and/or a cardiac resynchronization device that only benefits heart failure patients with a specific EKG pattern.
Loading...